StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Performance

NERV opened at $1.87 on Wednesday. The firm has a market cap of $13.04 million, a P/E ratio of -4.24 and a beta of 0.10. Minerva Neurosciences has a fifty-two week low of $1.42 and a fifty-two week high of $3.69. The firm has a 50-day moving average of $1.94 and a 200 day moving average of $2.25.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. Equities research analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Northern Trust Corp lifted its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,878 shares of the biopharmaceutical company’s stock after buying an additional 13,829 shares during the quarter. Northern Trust Corp owned about 0.53% of Minerva Neurosciences worth $82,000 at the end of the most recent quarter. 34.56% of the stock is owned by hedge funds and other institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.